Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL.

One major goal of cancer genome sequencing is to identify key genes and pathways that drive tumor pathogenesis. Although many studies have identified candidate driver genes based on recurrence of mutations in individual genes, subsets of genes with nonrecurrent mutations may also be defined as putative drivers if they affect a single biological pathway. In this fashion, we previously identified Wnt signaling as significantly mutated through large-scale massively parallel DNA sequencing of chronic lymphocytic leukemia (CLL). Here, we use a novel method of biomolecule delivery, vertical silicon nanowires, to efficiently introduce small interfering RNAs into CLL cells, and interrogate the effects of 8 of 15 mutated Wnt pathway members identified across 91 CLLs. In HEK293T cells, mutations in 2 genes did not generate functional changes, 3 led to dysregulated pathway activation, and 3 led to further activation or loss of repression of pathway activation. Silencing 4 of 8 mutated genes in CLL samples harboring the mutated alleles resulted in reduced viability compared with leukemia samples with wild-type alleles. We demonstrate that somatic mutations in CLL can generate dependence on this pathway for survival. These findings support the notion that nonrecurrent mutations at different nodes of the Wnt pathway can contribute to leukemogenesis.

[1]  Raul Rabadan,et al.  Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.

[2]  Jacob T. Robinson,et al.  Nanowire-Mediated Delivery Enables Functional Interrogation of Primary Immune Cells: Application to the Analysis of Chronic Lymphocytic Leukemia , 2012, Nano letters.

[3]  J. Rosenfeld,et al.  Mutations in prickle orthologs cause seizures in flies, mice, and humans. , 2011, American journal of human genetics.

[4]  A. Kozubík,et al.  The planar cell polarity pathway drives pathogenesis of chronic lymphocytic leukemia by the regulation of B-lymphocyte migration. , 2013, Cancer research.

[5]  Gerald L. Arthur,et al.  Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia , 2012, Epigenetics.

[6]  Paolo Vineis,et al.  Genome-wide Association Study Identifies Multiple Risk Loci for Chronic Lymphocytic Leukemia , 2013, Nature Genetics.

[7]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[8]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[9]  Albert Gutierrez,et al.  LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. , 2010, Blood.

[10]  T. Kipps,et al.  Ethacrynic Acid Exhibits Selective Toxicity to Chronic Lymphocytic Leukemia Cells by Inhibition of the Wnt/β-Catenin Pathway , 2009, PloS one.

[11]  M. Hallek,et al.  Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. , 2010, Neoplasia.

[12]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[13]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[14]  L. Pasqualucci,et al.  Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. , 2011, Blood.

[15]  Marc W. Kirschner,et al.  Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling , 2009, Nature.

[16]  W. Birchmeier,et al.  Wnt signalling and its impact on development and cancer , 2008, Nature Reviews Cancer.

[17]  Jacob T. Robinson,et al.  Vertical silicon nanowires as a universal platform for delivering biomolecules into living cells , 2010, Proceedings of the National Academy of Sciences.

[18]  J. Hoheisel,et al.  Concurrent epigenetic silencing of wnt/β-catenin pathway inhibitor genes in B cell chronic lymphocytic leukaemia , 2012, BMC Cancer.

[19]  M. Hallek,et al.  Small Molecule Inhibitors of Wnt/β-Catenin/Lef-1 Signaling Induces Apoptosis in Chronic Lymphocytic Leukemia Cells In Vitro and In Vivo , 2010 .

[20]  Frank Petersen,et al.  Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex , 2004 .

[21]  E. Ranheim,et al.  Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia. , 2007, Blood.

[22]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[23]  Alfonso Valencia,et al.  Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia , 2012, Nature Genetics.

[24]  Guy Cavet,et al.  Comment on "The Consensus Coding Sequences of Human Breast and Colorectal Cancers" , 2007, Science.

[25]  R Grosschedl,et al.  Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. , 2000, Immunity.

[26]  T. Kipps,et al.  Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Liang,et al.  Epigenetic dysregulation of the Wnt signalling pathway in chronic lymphocytic leukaemia , 2008, Journal of Clinical Pathology.

[28]  O. Galm,et al.  CpG island methylation patterns in chronic lymphocytic leukemia , 2009, Leukemia & lymphoma.

[29]  Brandi A. Thompson,et al.  CHD8 Is an ATP-Dependent Chromatin Remodeling Factor That Regulates β-Catenin Target Genes , 2008, Molecular and Cellular Biology.

[30]  Jian Li,et al.  Dysregulation of TNFα-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1 , 2010, Leukemia.

[31]  Jeffrey J Meyer,et al.  Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012. (5) , 2013 .

[32]  K. Basler,et al.  β-Catenin hits chromatin: regulation of Wnt target gene activation , 2009, Nature Reviews Molecular Cell Biology.

[33]  A. Regev,et al.  Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia , 2012, Clinical Cancer Research.

[34]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[35]  A. Sivachenko,et al.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.

[36]  Joshua C. Gilbert,et al.  An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules , 2013, Cell.

[37]  E. Giné,et al.  Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.

[38]  Randall T. Moon,et al.  Proximal events in Wnt signal transduction , 2009, Nature Reviews Molecular Cell Biology.

[39]  Frank Petersen,et al.  Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. , 2004, Cancer cell.

[40]  D. Neuberg,et al.  CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells , 2012, Cancer Immunology, Immunotherapy.

[41]  Jie J. Zheng,et al.  Structural Insight into the Mechanisms of Wnt Signaling Antagonism by Dkk* , 2008, Journal of Biological Chemistry.